Answers are grounded in this paper and cite their sources.
A 25-year-old male (Figure 1) with a history of recurrent pericardial effusions status after pericardectomy, limited joint mobility, cognitive deficiency, frequent airway infections, and multiple airway stenoses (recurrent progressive tracheal stenosis and bilateral choanal atresia) was evaluated for dyspnea in the emergency department. Chest computed tomography showed complete collapse of the left lung and postobstructive pneumonia secondary to stenosis of the following areas: left main bronchus (99%), subglottis and mid-trachea (75%), and bronchus intermedius (35%) (Figures 2A and 2B). Seven hours after admission, the patient developed respiratory failure requiring intubation under bronchoscopic guidance (Figures 2C and 2D). Subsequently, he was transferred to the ICU requiring a tracheostomy, antibiotics, and intravenous steroids. Repeat bronchoscopy and airway tissue biopsy showed patchy chronic inflammation, mucosal fibrosis, hemosiderin deposition, and scattered eosinophils. Twenty days later, the patient was discharged on oral steroids. Because multiple anatomic abnormalities were observed, genetic testing was performed. This showed a c.1498A > G(p.Ile500Val) pathogenic variation in exon 12 of the SMAD4 gene (1), which codifies for the TGF-β signaling cascade consistent with Myhre syndrome (1, 2). Losartan (50 mg daily) was initiated based on its inhibitory effect on TGF-β (2). Etanercept (50 mg subcutaneous weekly), a TNF-α inhibitor, was started because it has been shown to be effective in decreasing cartilage inflammation in other autoimmune conditions, such as rheumatoid arthritis (3). Over the last 7 years, the patient has not experienced further episodes of respiratory failure; however, he still requires periodic (4–8 wk) bronchoscopy-guided balloon dilation and intralesional methyl prednisone (20 mg into each quadrant) for persistent symptoms and recurrent stenosis. Etanercept was discontinued because of recurrent pneumonia. Myhre syndrome presents as a life-threatening condition, with airway stenosis (reported in 15% of patients) and respiratory failure (in nearly 25% of patients) being the most common causes of death (4). Currently, there is no standardized treatment (5). Further studies are needed to evaluate the benefit of losartan or etanercept in this population. Some of the results of this study have been previously reported in the form of an abstract (6).
No takes yet. Share an insight, caveat, or question.
Alape et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: